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Nanoliposomes are new technological developments for the encapsulation and delivery of bioactive 
agents. Because of their biocompatibility and biodegradability, along with their size, nanoliposomes 
have potential applications in a vast range of fields, including nanotherapy. Nanoliposomes are able to 
enhance the performance of bioactive agents by improving their bioavailability, in vitro and in vivo 
stability, as well as preventing their unwanted interactions with other molecules [1].  
Nanoliposomes may contain, in addition to phospholipids, other molecules such as cholesterol (Ch) 
which is an important component of most natural membranes. The incorporation of Ch can increase 
stability by modulating the fluidity of the lipid bilayer preventing crystallization of the phospholipid acyl 
chains and providing steric hindrance to their movement. Further advances in liposome research found 
that polyethylene glycol (PEG), which is inert in the body, allows longer circulatory life of the drug 
delivery system [2].  
In this work, new potential antitumoral di(hetero)arylethers derivatives of a thieno[3,2-b]pyridine, 1 and 
2, synthesized by us, have been encapsulated in different nanoliposome formulations, composed of 
egg-yolk phosphatidylcholine (Egg-PC), dipalmitoyl phosphatidylcholine (DPPC), dioleoyl 
phosphatidylcholine (DOPC), dimyristoyl phosphatidylglycerol (DMPG), distearoyl phosphatidylcholine 
(DSPC), with or without Ch and distearoyl phosphatidylethanolamine-(polyethylene glycol)2000 (DSPE-
PEG).  
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Compounds 1 and 2 were evaluated for the in vitro cell growth inhibition on three human tumor cell 
lines, breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and a melanoma cell line 
(A375-C5), after a continuous exposure of 48 h, exhibiting very low GI50 values (µM) in the three tumor 
cell lines (Table 1). 
 
Table 1. Values of compounds 1 and 2 concentration   
               needed for 50% of cell growth inhibition (GI50). 
GI50 (µM) 
 MCF-7 NCI-H460 A375-C5 
1 1.4 ± 0.1 1.4 ± 0.2 1.1 ± 0.1 
2 2.5 ± 0.1 2.5 ± 0.3 2.3 ± 0.1 
                                                    Doxorubicin was used as control: GI50 MCF-7 = 43.3 ± 2.6 nM;  
                                              NCI-H460 = 130.2 ± 10.1 nM; A375-C5 = 35.6 ± 1.6 nM.  
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Nanoliposomes were prepared by injection of an ethanolic solution of the different lipid mixtures in 
aqueous media under vigorous stirring, above the melting transition temperature of the lipids, followed 
by six extrusion cycles through 100 nm polycarbonate membranes. Dynamic light scattering (DLS) 
measurements indicated that the nanoliposomes with the incorporated compound are generally 
monodisperse and with diameters between 70 nm and 120 nm.  
Compounds 1 and 2 exhibit fluorescence in non-polar media, while no emission is observed in protic 
solvents (like ethanol, methanol and water). The two compounds show significant emission when 
incorporated in nanoliposomes (Figure 1) and fluorescence anisotropy values are generally high. This 
behavior indicates that both compounds can be transported in the hydrophobic region of the lipid 
bilayer. These results may be important for future drug delivery applications of the new potential 
antitumoral di(hetero)aryletherthienopyridines, using nanoliposomes as drug carriers. 
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Figures 
 
Figure 1. Normalized fluorescence spectra of compounds 1 and 2 in several nanoliposome formulations.  
